Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2012 | 12-2011 | 09-2011 | 06-2011 | 03-2011 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 116,608 | 52,826 | 66,329 | 79,117 | 73,829 |
| Receivables | 5,551 | 2,263 | 6,238 | 4,496 | 1,731 |
| Inventories | 1,497 | 567 | 103 | 84 | 249 |
| TOTAL | $132,566 | $63,988 | $76,969 | $88,014 | $79,192 |
| Non-Current Assets | |||||
| PPE Net | 2,153 | 1,771 | 1,275 | 1,496 | 1,741 |
| TOTAL | $2,153 | $1,771 | $1,275 | $1,496 | $1,741 |
| Total Assets | $134,719 | $65,759 | $78,243 | $89,509 | $80,933 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,011 | 7,557 | 1,220 | 1,732 | 1,451 |
| Accrued Expenses | 7,185 | 5,616 | 8,865 | 9,466 | 8,238 |
| TOTAL | $16,681 | $17,302 | $13,792 | $31,543 | $12,604 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 6,485 | 4,129 | 3,708 | 20,346 | 2,915 |
| TOTAL | $36,978 | $37,557 | $37,396 | $37,913 | $54,814 |
| Total Liabilities | $53,659 | $54,858 | $51,188 | $69,456 | $67,418 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 112,443 | 112,094 | 103,692 | 103,620 | 102,805 |
| Common Shares | 112 | 104 | 104 | 104 | 102 |
| Retained earnings | -260,141 | -245,022 | -226,606 | -231,771 | -234,888 |
| TOTAL | $81,060 | $10,900 | $27,055 | $20,053 | $13,515 |
| Total Liabilities And Equity | $134,719 | $65,759 | $78,243 | $89,509 | $80,933 |